EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phosphoproteomic profiling of early rheumatoid arthritis synovium reveals active signalling pathways and differentiates inflammatory pathotypes

Cankut Çubuk, Rachel Lau, Pedro Cutillas, Vinothini Rajeeve, Christopher R John, Anna E A Surace, Rebecca Hands, Liliane Fossati-Jimack, Myles J Lewis, Costantino Pitzalis

Arthritis Research & Therapy · 2024

DOI: 10.1186/s13075-024-03351-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Research & Therapy, 2024. Verfasst von Cankut Çubuk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust,…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Synovial Membrane, Signal Transduction, Proteomics. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Barts and The London School of Medicine and Dentistry, Medical Research Council, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kinases are intracellular signalling mediators and key to sustaining the inflammatory process in rheumatoid arthritis (RA). Oral inhibitors of Janus Kinase family (JAKs) are widely used in RA, while inhibitors of other kinase families e.g. phosphoinositide 3-kinase (PI3K) are under development. Most current biomarker platforms quantify mRNA/protein levels, but give no direct information on whether proteins are active/inactive. Phosphoproteome analysis has the potential to measure specific enzyme activation status at tissue level.

Methods

We validated the feasibility of phosphoproteome and total proteome analysis on 8 pre-treatment synovial biopsies from treatment-naive RA patients using label-free mass spectrometry, to identify active cell signalling pathways in synovial tissue which might explain failure to respond to RA therapeutics.

Results

Differential expression analysis and functional enrichment revealed clear separation of phosphoproteome and proteome profiles between lymphoid and myeloid RA pathotypes. Abundance of specific phosphosites was associated with the degree of inflammatory state. The lymphoid pathotype was enriched with lymphoproliferative signalling phosphosites, including Mammalian Target Of Rapamycin (MTOR) signalling, whereas the myeloid pathotype was associated with Mitogen-Activated Protein Kinase (MAPK) and CDK mediated signalling. This analysis also highlighted novel kinases not previously linked to RA, such as Protein Kinase, DNA-Activated, Catalytic Subunit (PRKDC) in the myeloid pathotype. Several phosphosites correlated with clinical features, such as Disease-Activity-Score (DAS)-28, suggesting that phosphosite analysis has potential for identifying novel biomarkers at tissue-level of disease severity and prognosis.

Conclusions

Specific phosphoproteome/proteome signatures delineate RA pathotypes and may have clinical utility for stratifying patients for personalised medicine in RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidSynovial MembraneSignal TransductionProteomicsPhosphoproteinsHumansFemaleMiddle AgedMaleAdultAgedProteome

Substanzen

PhosphoproteinsProteome

Autor:innen und Institutionen

  • Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, Charterhouse Square, London, EC1M 6BQ, UK.
  • Cell Signalling and Proteomics Group, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK.
  • Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, Charterhouse Square, London, EC1M 6BQ, UK. myles.lewis@qmul.ac.uk.
  • Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, Charterhouse Square, London, EC1M 6BQ, UK. c.pitzalis@qmul.ac.uk.
  • IRCCS Istituto Clinico Humanitas, Via Manzoni 56, Rozzao, Milan, Italy. c.pitzalis@qmul.ac.uk.

Förderung

  • Barts and The London School of Medicine and Dentistry
  • Medical Research Council
  • National Institute for Health and Care Research
  • Arthritis Research UK
  • Cancer Research UK

Zitieren

APA

Çubuk, C., Lau, R., Cutillas, P., Rajeeve, V., John, C. R., Surace, A. E. A., Hands, R., Fossati-Jimack, L., Lewis, M. J., & Pitzalis, C. (2024). Phosphoproteomic profiling of early rheumatoid arthritis synovium reveals active signalling pathways and differentiates inflammatory pathotypes. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03351-4

Vancouver

Çubuk C, Lau R, Cutillas P, Rajeeve V, John CR, Surace AEA, et al. Phosphoproteomic profiling of early rheumatoid arthritis synovium reveals active signalling pathways and differentiates inflammatory pathotypes. Arthritis Research & Therapy. 2024. doi:10.1186/s13075-024-03351-4

BibTeX
@article{ubuk2024,
  author = {Çubuk, Cankut and Lau, Rachel and Cutillas, Pedro and Rajeeve, Vinothini and John, Christopher R and Surace, Anna E A and Hands, Rebecca and Fossati-Jimack, Liliane and Lewis, Myles J and Pitzalis, Costantino},
  title = {Phosphoproteomic profiling of early rheumatoid arthritis synovium reveals active signalling pathways and differentiates inflammatory pathotypes},
  journal = {Arthritis Research & Therapy},
  year = {2024},
  doi = {10.1186/s13075-024-03351-4}
}
Kostenlos starten →